[go: up one dir, main page]

DE69430951D1 - Zusammensetzung enthaltend bradykinin zum selektiven offnen von anormalen gehirngewebes kapillaren - Google Patents

Zusammensetzung enthaltend bradykinin zum selektiven offnen von anormalen gehirngewebes kapillaren

Info

Publication number
DE69430951D1
DE69430951D1 DE69430951T DE69430951T DE69430951D1 DE 69430951 D1 DE69430951 D1 DE 69430951D1 DE 69430951 T DE69430951 T DE 69430951T DE 69430951 T DE69430951 T DE 69430951T DE 69430951 D1 DE69430951 D1 DE 69430951D1
Authority
DE
Germany
Prior art keywords
brain tissue
abnormal brain
bradykinin
capillar
composition containing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69430951T
Other languages
English (en)
Other versions
DE69430951T2 (de
Inventor
Keith L Black
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Application granted granted Critical
Publication of DE69430951D1 publication Critical patent/DE69430951D1/de
Publication of DE69430951T2 publication Critical patent/DE69430951T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/043—Kallidins; Bradykinins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
DE69430951T 1993-05-10 1994-04-19 Zusammensetzung enthaltend bradykinin zum selektiven offnen von anormalen gehirngewebes kapillaren Expired - Fee Related DE69430951T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/059,623 US5434137A (en) 1993-05-10 1993-05-10 Method for selective opening of abnormal brain tissue capillaries
PCT/US1994/004269 WO1994027133A1 (en) 1993-05-10 1994-04-19 Method for selective opening of abnormal brain tissue capillaries

Publications (2)

Publication Number Publication Date
DE69430951D1 true DE69430951D1 (de) 2002-08-14
DE69430951T2 DE69430951T2 (de) 2003-03-27

Family

ID=22024161

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69430951T Expired - Fee Related DE69430951T2 (de) 1993-05-10 1994-04-19 Zusammensetzung enthaltend bradykinin zum selektiven offnen von anormalen gehirngewebes kapillaren

Country Status (9)

Country Link
US (2) US5434137A (de)
EP (1) EP0698203B1 (de)
JP (1) JPH08509978A (de)
AT (1) ATE220329T1 (de)
AU (1) AU679530B2 (de)
CA (1) CA2162055A1 (de)
DE (1) DE69430951T2 (de)
ES (1) ES2179843T3 (de)
WO (1) WO1994027133A1 (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5543390A (en) * 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University Covalent microparticle-drug conjugates for biological targeting
US5827819A (en) 1990-11-01 1998-10-27 Oregon Health Sciences University Covalent polar lipid conjugates with neurologically active compounds for targeting
AU732043B2 (en) * 1996-11-20 2001-04-12 Yissum Research Development Company Of The Hebrew University Of Jerusalem A method and composition for enabling passage through the blood-brain barrier
US6043223A (en) * 1997-11-12 2000-03-28 The Regents Of The University Of California Enhanced opening of abnormal brain tissue capillaries
US6774119B1 (en) * 1999-04-26 2004-08-10 Cedars-Sinai Medical Center Herpes simplex virus type 1 (hsv-1)-derived vector for selectively inhibiting malignant cells and methods for its use to treat cancers and to express desired traits in malignant and non-malignant mammalian cells
US20050153940A1 (en) * 2000-01-26 2005-07-14 Cedars-Sinai Medical Center Method for using potassium channel activation for delivering a medicant to an abnormal brain region and/or a malignant tumor
US7018979B1 (en) 2000-01-26 2006-03-28 Cedars-Sinai Medical Center Method for using potassium channel agonists for delivering a medicant to an abnormal brain region and/or a malignant tumor
AU2002247127A1 (en) * 2001-02-14 2002-08-28 Duke University Therapy for cerebral vasospasm
US7211561B2 (en) * 2001-10-12 2007-05-01 Cedars-Sinai Medical Center Method for inducing selective cell death of malignant cells by activation of calcium-activated potassium channels (KCa)
US7045543B2 (en) 2001-11-05 2006-05-16 Enzrel Inc. Covalent conjugates of biologically-active compounds with amino acids and amino acid derivatives for targeting to physiologically-protected sites
US7244764B2 (en) * 2003-06-23 2007-07-17 Neurochem (International) Limited Methods and compositions for treating amyloid-related diseases
US7414076B2 (en) * 2003-06-23 2008-08-19 Neurochem (International) Limited Methods and compositions for treating amyloid-related diseases
US20070010573A1 (en) * 2003-06-23 2007-01-11 Xianqi Kong Methods and compositions for treating amyloid-related diseases
US20050074506A1 (en) * 2003-10-02 2005-04-07 Brainsgate Ltd. Targeted release of nitric oxide in the CNS circulation for modulating the BBB and treating disorders
US20050095196A1 (en) * 2003-10-29 2005-05-05 Black Keith L. Method for using potassium channel agonists for delivering a medicant to an abnormal brain region and/or a malignant tumor
MX2007005507A (es) * 2004-11-12 2008-03-13 Neurochem Int Ltd Metodos y composiciones fluoradas para el tratamiento de padecimientos relacionados con amiloides.
CN101103018A (zh) * 2004-11-16 2008-01-09 神经化学（国际）有限公司 治疗cns和淀粉样蛋白-相关疾病的化合物
JP5145537B2 (ja) 2004-12-22 2013-02-20 ビーエイチアイ リミテッド パートナーシップ アミロイド関連疾患を治療するための方法および組成物
US20080188480A1 (en) * 2005-02-22 2008-08-07 Cedars-Sinai Medical Center Use of Sildenafil, Vardenafil and Other 5-Phosphodiesterase Inhibitors to Enhance Permeability of the Abnormal Blood-Brain Barrier
US20070232556A1 (en) * 2006-03-31 2007-10-04 Montine Thomas J Methods and compositions for the treatment of neurological diseases and disorders
US20100316626A1 (en) * 2006-08-11 2010-12-16 The Government Of The United States Of America As Represented By The Secretary Methods for treatment and diagnosis of psychiatric disorders
EP2089417B1 (de) 2006-10-12 2014-12-31 BHI Limited Partnership Verfahren, verbindungen, zusammensetzungen und vehikel zur verabreichung von 3-amino-1-propansulfonsäure
EP2157911A2 (de) 2007-05-16 2010-03-03 Yeda Research And Development Co. Ltd. Beurteilung einer störung der blut-gehirn-schranke
EP2342356A4 (de) 2008-09-29 2012-11-21 Univ Ben Gurion Amyloid-beta-peptidasen und verwendungsverfahren dafür
US9147246B2 (en) 2009-08-18 2015-09-29 Ben-Gurion University Of The Negev Research And Development Authority Apparatus and method for analyzing stream of imaging data
US10275680B2 (en) 2011-10-19 2019-04-30 Tel Hashomer Medical Research Infrastructure And Services Ltd. Magnetic resonance maps for analyzing tissue
JP6526627B2 (ja) 2013-04-24 2019-06-05 テル ハショメール メディカル リサーチ インフラストラクチャー アンド サービシズ リミテッド 組織解析用の磁気共鳴マップ
WO2015042119A1 (en) * 2013-09-19 2015-03-26 Burt Tal Systems and methods for intra-target microdosing (itm)
CN110997693A (zh) 2017-06-07 2020-04-10 阿德克斯公司 τ聚集抑制剂
EP3668886A2 (de) 2017-08-18 2020-06-24 Adrx, Inc. Peptidinhibitoren der tau-aggregation

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5112596A (en) * 1990-04-23 1992-05-12 Alkermes, Inc. Method for increasing blood-brain barrier permeability by administering a bradykinin agonist of blood-brain barrier permeability
US5268164A (en) * 1990-04-23 1993-12-07 Alkermes, Inc. Increasing blood-brain barrier permeability with permeabilizer peptides

Also Published As

Publication number Publication date
JPH08509978A (ja) 1996-10-22
US5434137A (en) 1995-07-18
EP0698203A4 (de) 1997-02-26
EP0698203A1 (de) 1996-02-28
US5527778A (en) 1996-06-18
DE69430951T2 (de) 2003-03-27
EP0698203B1 (de) 2002-07-10
WO1994027133A1 (en) 1994-11-24
ES2179843T3 (es) 2003-02-01
ATE220329T1 (de) 2002-07-15
CA2162055A1 (en) 1994-11-24
AU6770194A (en) 1994-12-12
AU679530B2 (en) 1997-07-03

Similar Documents

Publication Publication Date Title
DE69430951D1 (de) Zusammensetzung enthaltend bradykinin zum selektiven offnen von anormalen gehirngewebes kapillaren
MX9706069A (es) Nuevos inhibidores de la trombina.
DE69628556D1 (de) Tricyclische verbindungen als inhibitoren von farnesyl protein transferase
PH31263A (en) Methods of inhibiting vascular smooth muscle cell proliferation and restinosis.
LV10183A (lv) Perorala kompozicija zarnu iekaisuma slimibu arstesanai
FR2591485B1 (fr) Compositions stabilisees contenant l'activateur du plasminogene du tissu humain.
DE3376524D1 (en) Skin treatment composition
IL112037A0 (en) Methods of inhibiting dysfunctional uterine bleeding
UA27910C2 (uk) Засіб для підвищення експресії тромбомодуліну та підвищення активації протеїну с
NO20011946D0 (no) Mangansammensetninger og fremgangsmåter for MRI
NO962655L (no) Deutrerte virkestoffer i transdermal applikasjon
MX9709466A (es) Medicamento para inhibir el melanoma.
ES8800725A1 (es) Un procedimiento para producir un anticuerpo monoclonal
TR199801184T2 (xx) Analjezik tesirli yeni bile�ikler.
AU7439996A (en) Novel uses of mammalian ctla-8 and related reagents
MY113406A (en) Methods of inhibiting physiological conditions associated with an excess of bradykinin
MX9701606A (es) Terapia de combinacion para evitar la perdida osea-progesterona y agonistas de estrogeno.
EP0340933A3 (de) Heparin enthaltende Formulierungen
IL98200A0 (en) Pharmaceutical composition containing a derivative of substituted-l-valyl-l-prolinamide
DK0644768T3 (da) Fremgangsmåder og præparater til inhibering af endotelcelle- og fibrinogenfremkaldt inflammation
GB1526382A (en) Transpentenenitrile compounds having antidiarrheal activity
DE69001240D1 (de) Methoden zur verwendung von 2-isopropyl-2-phenylaminovaleriansaeurenitrilen als immunosupressoren und vasodilatoren.
MX9700626A (es) USO DE AZASPIRANOS EN LA REPARACIaN DE COMPOSICIONES PARA TRATAR INFECCIONES OPORTUNISTAS.
IT8423800A1 (it) Procedimento di trattamento di stati ipotrofici nel bambino mediante somministrazioni di aspartato di arginina
EP1616564A3 (de) Beeinflussung von nitrosativem Stress zur Behandlung von Mikroorganismen und Helminthen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee